Scenic Biotech

Scenic Biotech is a biotechnology firm specializing in 'modifier therapy,' an approach to treating genetic disorders by targeting genes that can suppress the effects of a disease-causing mutation. Founded in 2017 as a spin-out from the Netherlands Cancer Institute and the University of Oxford, the Amsterdam-based company was established by Sebastian Nijman and Thijn Brummelkamp.

The company's core technology is the proprietary Cell-Seq platform, a functional genomics tool used to identify these genetic modifiers, also known as disease suppressors. This platform creates high-resolution 'disease maps' that profile biological pathways and help uncover novel drug targets. Unlike treatments that target the primary faulty gene, modifier therapy aims to rebalance health by acting on another part of the genome that naturally counteracts the disease's impact. The technology uses special human cells with a single copy of each gene to systematically identify genes that influence disease-causing pathways.

Scenic Biotech's business model involves developing its own pipeline of wholly-owned small molecule programs while also leveraging its Cell-Seq platform through strategic collaborations with major pharmaceutical companies. These partnerships provide upfront payments, milestone fees, and potential royalties, helping to fund internal development. The company has established multi-year agreements with Genentech (a member of the Roche Group), Bristol Myers Squibb, Alnylam Pharmaceuticals, and Ono Pharmaceutical to discover new therapeutic targets.

The company's internal pipeline is focused on severe diseases, including neuro-metabolic and metabolic disorders like Niemann-Pick type C and Barth syndrome, as well as immuno-oncology. Its most advanced program is a small-molecule inhibitor targeting PLA2G15 for rare disorders such as Batten disease and Niemann-Pick type C. Scenic Biotech has raised significant funding, including a Series A round, to advance its programs toward clinical trials.

Keywords: modifier therapy, genetic modifiers, Cell-Seq platform, rare genetic diseases, drug discovery, functional genomics, small molecules, neuro-metabolic disorders, metabolic diseases, immuno-oncology, Niemann-Pick disease, Barth syndrome, Batten disease, PLA2G15 inhibitor, Genentech collaboration, Bristol Myers Squibb collaboration, Alnylam collaboration, Ono Pharmaceutical collaboration, target identification, disease suppressors